Kimberly J. Popovits Sells 20,000 Shares of Genomic Health, Inc. (GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) CEO Kimberly J. Popovits sold 20,000 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $31.50, for a total transaction of $630,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Genomic Health, Inc. (NASDAQ GHDX) opened at $36.21 on Wednesday. Genomic Health, Inc. has a twelve month low of $26.37 and a twelve month high of $37.50.

Several institutional investors and hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new position in shares of Genomic Health in the 3rd quarter valued at about $444,000. GSA Capital Partners LLP increased its holdings in Genomic Health by 43.7% in the third quarter. GSA Capital Partners LLP now owns 63,100 shares of the medical research company’s stock worth $2,025,000 after buying an additional 19,200 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Genomic Health in the third quarter worth approximately $138,000. Point72 Asset Management L.P. acquired a new position in Genomic Health in the third quarter worth approximately $350,000. Finally, Jane Street Group LLC acquired a new position in Genomic Health in the third quarter worth approximately $227,000. Institutional investors own 89.61% of the company’s stock.

Several research firms have issued reports on GHDX. BidaskClub upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday. Jefferies Group restated a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a report on Friday, October 20th. ValuEngine upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, December 15th. Zacks Investment Research upgraded Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, October 13th. Finally, Cowen restated a “hold” rating and set a $34.00 price objective on shares of Genomic Health in a report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. Genomic Health currently has a consensus rating of “Hold” and a consensus target price of $31.57.

COPYRIGHT VIOLATION WARNING: “Kimberly J. Popovits Sells 20,000 Shares of Genomic Health, Inc. (GHDX) Stock” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://sportsperspectives.com/2017/12/20/kimberly-j-popovits-sells-20000-shares-of-genomic-health-inc-ghdx-stock.html.

Genomic Health Company Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply